Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics Inc (AXSM – Research Report), Amgen Inc (AMGN – Research Report) and Allakos Inc (ALLK – Research Report).
Axsome Therapeutics Inc (AXSM)
William Blair analyst Myles Minter maintained a Buy rating on Axsome Therapeutics Inc on October 28. The company’s shares closed last Monday at $24.68.
According to TipRanks.com, Minter is ranked #4636 out of 5587 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics Inc with a $37.75 average price target, a 55.7% upside from current levels. In a report issued on October 16, Guggenheim also initiated coverage with a Buy rating on the stock with a $48.00 price target.
Amgen Inc (AMGN)
William Blair analyst Matt Phipps maintained a Hold rating on Amgen Inc on October 29. The company’s shares closed last Monday at $215.88, close to its 52-week high of $217.00.
According to TipRanks.com, Phipps ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -17.7% and a 35.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Autolus Therapeutics Plc, and Kezar Life Sciences Inc.
Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $225.29, representing a 5.1% upside. In a report issued on October 16, Merrill Lynch also initiated coverage with a Hold rating on the stock with a $215.00 price target.
Allakos Inc (ALLK)
In a report issued on October 29, Tim Lugo from William Blair maintained a Buy rating on Allakos Inc. The company’s shares closed last Monday at $69.61.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 5.4% and a 38.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Collegium Pharmaceutical.
Currently, the analyst consensus on Allakos Inc is a Moderate Buy with an average price target of $89.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.